A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
This study evaluated once-daily, extended-release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder (GAD). This was a 10-week (8-week active treatment/2-week posttreatment drug-discontinuation/tapering phase), double-blind, randomized, placebo-controlled study (D1448C00009). Primary end point was change from randomization at week 8 in Hamilton Anxiety Rating Scale (HAM-A) total score. Overall, 951 patients with GAD were randomized (quetiapine XR: 50 mg/d, n = 234; 150 mg/d, n = 241; 300 mg/d, n = 241; placebo, n = 235). At week 8, HAM-A total scores significantly (P < 0.001) improved versus placebo (-11.10) with quetiapine XR 50 mg/d (-13.31) and 150 mg/d (-13.54), but not 300 mg/d (-11.87; P = 0.240). At week 1, HAM-A total scores significantly improved versus placebo (-5.94) with quetiapine XR 50 mg/d (-7.47; P < 0.01), 150 mg/d (-8.19; P < 0.001), and 300 mg/d (-7.23; P < 0.01). Versus placebo at week 8, quetiapine XR 50 and 150 mg/d significantly improved HAM-A psychic (P < 0.01 and P < 0.001, respectively) and somatic (P < 0.001; P < 0.01, respectively) cluster scores, HAM-A response (≥ 50% total score reduction; P < 0.05), and Clinical Global Impression-Improvement categorical changes (P < 0.05). For quetiapine XR 150 mg/d, significant (P < 0.05) improvements were seen for HAM-A remission (total score, ≤ 7) and Clinical Global Impression-Severity of Illness scores. For quetiapine XR 300 mg/d, improvements in these secondary variables were not significantly different versus placebo. Pittsburgh Sleep Quality Index global scores improved with all 3 doses (quetiapine: XR 50 mg/d, -4.07 [P < 0.05]; 150 mg/d, -4.38 [P < 0.05]; 300 mg/d, -3.97 [P < 0.05], versus -3.31 with placebo). Adverse events (>10% with quetiapine XR) were dry mouth, somnolence, sedation, dizziness, headache, and fatigue. Quetiapine XR (50/150 mg/d) monotherapy was effective at week 8 in patients with GAD; symptom improvement was seen at week 1 for all doses (50/150/300 mg/d). Safety and tolerability were consistent with the known profile of quetiapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Quality-of-Life Impairment in Depressive and Anxiety Disorders
Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1171 · Cited by 914
Risk factors for suicidality in Europe: Results from the ESEMED study
Bernal, M., Haro, J. M., Bernert, S., Brugha, T., de Graaf, R., Bruffaerts, R., Lépine, J. P., de Girolamo, G., Vilagut, G., Gasquet, I., et al. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.09.018 · Cited by 565
Wittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00002 · Cited by 299
Keller, A., McGarvey, E. L., & Clayton, A. H. (2006) · Journal of Sex & Marital Therapy · doi:10.1080/00926230500232909 · Cited by 243
Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235 · cited 1×
“Selective serotonin reuptake inhibitors and SNRIs are known to cause sexual dysfunction,(13) which is a commonly cited reason for discontinuing treatment.(54,55) For quetiapine XR, the incidence of and discontinuations due to AEs potentially related to sexual dysfunction were low, and changes in mean CSFQ scores and p…”
ResultBauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
Impairment and quality of life in individuals with generalized anxiety disorder
Henning, E. R., Turk, C. L., Mennin, D. S., Fresco, D. M., & Heimberg, R. G. (2007) · Depression and Anxiety · doi:10.1002/da.20249 · Cited by 189
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Self-citation
Research works printed but not linked: 41
- Grant, 2005, Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions., Psychol Med, 35, 1747, 10.1017/S0033291705006069 · DOI · Paper page
- Belanger, 2005, Generalized anxiety disorder and health care use., Can Fam Physician, 51, 1362
- Kessler, 1999, Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys., Am J Psychiatry, 156, 1915, 10.1176/ajp.156.12.1915 · DOI · Paper page
- Wittchen, 2002, Generalized anxiety and depression in primary care: prevalence, recognition, and management., J Clin Psychiatry, 63, 24
- Ninan, 2001, Dissolving the burden of generalized anxiety disorder., J Clin Psychiatry, 62, 5
- Bandelow, 2008, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision., World J Biol Psychiatry, 9, 248, 10.1080/15622970802465807 · DOI · Paper page
- Ball, 2005, Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline., J Clin Psychiatry, 66, 94, 10.4088/JCP.v66n0113 · DOI · Paper page
- Ballenger, 2001, Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety., J Clin Psychiatry, 62, 53
- Gorman, 2003, Treating generalized anxiety disorder., J Clin Psychiatry, 64, 24
- Chouinard, 2004, Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound., J Clin Psychiatry, 65, 7
- Merideth, 2008, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalised anxiety disorder (GAD) abstract., Eur Neuropsychopharmacol, 18, S499, 10.1016/S0924-977X(08)70749-1 · DOI
- Magi, 2009, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD) asbtract., World J Biol Psychiatry, 10, 239
- Katzman, 2011, Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial., Int Clin Psychopharmacol, 26, 11, 10.1097/YIC.0b013e32833e34d9 · DOI · Paper page
- Richelson, 2000, Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds., Life Sci, 68, 29, 10.1016/S0024-3205(00)00911-5 · DOI · Paper page
- Nyberg, 2010, Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties., Eur Psychiatry, 25, 1446, 10.1016/S0924-9338(10)71429-2 · doi:10.1016/s0924-9338(10)71429-2
- Jensen, 2008, N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity., Neuropsychopharmacology, 33, 2303, 10.1038/sj.npp.1301646 · DOI · Paper page
- 2001, Helsinki: ethical principles for medical research involving human subjects (revised October 7, 2000)., HIV Clin Trials, 2, 92, 10.1310/GTFR-2DRX-M6YE-ELXR · DOI · Paper page
- Hamilton, 1959, The assessment of anxiety states by rating., Br J Med Psychol, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- Buysse, 1989, The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research., Psychiatry Res, 28, 193, 10.1016/0165-1781(89)90047-4 · DOI · Paper page
- Ritsner, 2005, Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients., Qual Life Res, 14, 1693, 10.1007/s11136-005-2816-9 · DOI · Paper page
- Barnes, 1989, A rating scale for drug-induced akathisia., Br J Psychiatry, 154, 672, 10.1192/bjp.154.5.672 · DOI · Paper page
- Simpson, 1970, A rating scale for extrapyramidal side effects., Acta Psychiatr Scand Suppl, 212, 11, 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
- Hoehn-Saric, 1988, Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms., J Clin Psychiatry, 49, 293
- Rickels, 1993, Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam., Arch Gen Psychiatry, 50, 884, 10.1001/archpsyc.1993.01820230054005 · DOI · Paper page
- Rocca, 1997, Paroxetine efficacy in the treatment of generalized anxiety disorder., Acta Psychiatr Scand, 95, 444, 10.1111/j.1600-0447.1997.tb09660.x · DOI · Paper page
- Greenwood, 2008, Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise., Psychopharmacology (Berl), 199, 209, 10.1007/s00213-008-1167-y · DOI
- Papadimitriou, 2005, Sleep disturbance in anxiety disorders., Int Rev Psychiatry, 17, 229, 10.1080/09540260500104524 · DOI · Paper page
- Benca, 2001, Consequences of insomnia and its therapies., J Clin Psychiatry, 62, 33
- Maier, 2000, Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?, Acta Psychiatr Scand, 101, 29, 10.1034/j.1600-0447.2000.101001029.x · DOI · Paper page
- Liebowitz, 2010, Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial., Depress Anxiety, 27, 964, 10.1002/da.20740 · DOI · Paper page
- Katila, 2009, Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD) abstract., World J Biol Psychiatry, 10, 225
- Bortnick, 2011, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study published online ahead of print August 4, 2010., J Affect Disord, 128, 83, 10.1016/j.jad.2010.06.031 · DOI
- Cutler, 2009, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study., J Clin Psychiatry, 70, 526, 10.4088/JCP.08m04592 · DOI · Paper page
- Weisler, 2009, Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study., CNS Spectr, 14, 299, 10.1017/S1092852900020307 · DOI · Paper page
- El-Khalili, 2010, Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study., Int J Neuropsychopharmacol, 13, 917, 10.1017/S1461145710000015 · DOI · Paper page
- Kahn, 2007, Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study., J Clin Psychiatry, 68, 832, 10.4088/JCP.v68n0603 · DOI · Paper page
- Casey, 2006, Implications of the CATIE trial on treatment: extrapyramidal symptoms., CNS Spectr, 11, 25, 10.1017/S1092852900026651 · DOI
- Barnes, 1998, Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia., Int Clin Psychopharmacol, 13, S49, 10.1097/00004850-199803003-00009 · DOI
- Sachdev, 2004, Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study., Aust N Z J Psychiatry, 38, 445, 10.1080/j.1440-1614.2004.01382.x · DOI
- Lane, 1998, SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment., J Psychopharmacol, 12, 192, 10.1177/026988119801200212 · DOI · Paper page
- Harvey, 1995, Clinical implications of antidepressant drug effects on sexual function., Ann Clin Psychiatry, 7, 189, 10.3109/10401239509149625 · DOI
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“of quetiapine XR for the management of GAD (Level 1) [551,557,602,603].”
BackgroundTreatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Albert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
Metadata
- Authors
- Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., & Eriksson, H.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-08
- Volume
- 31
- Issue
- 4
- Pages
- 418-428
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1965144024
- Cited by
- 66
- References
- 12
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e318224864d
- The paper
- Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., & Eriksson, H. (2011). A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318224864d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.